Initiation of LHRH monotherapy for prostate cancer.
Milsted
R A
RA
Imperial Chemical Industries PLC, Macclesfield, Cheshire, UK.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol; D005485:Flutamide; D003534:Cyproterone